A real‐world study of immune thrombocytopenia management during the COVID‐19 pandemic in the UK

作者：Alexandros Rampotas, Edmund Watson, Kieran Burton, Quentin A. Hill, Sue Pavord · 发表于：British Journal of Haematology · 年份：2021 · DOI：10.1111/bjh.17804 · 被引用次数：17 · 研究领域：Platelet Disorders and Treatments、Blood groups and transfusion、Heparin-Induced Thrombocytopenia and Thrombosis

The COVID-19 pandemic has created many challenges in the management of immune thrombocytopenic purpura (ITP). The recommendation for avoidance of steroids by WHO led to the off-licence use, supported by NHS England, of thrombopoietin mimetics (TPO-RA) for newly diagnosed or relapsed ITP. This is a real-world prospective study which investigated the treatment patterns and outcomes in this setting. Twenty-four hospitals across the UK submitted 343 cases. Corticosteroids remain the mainstay of ITP treatment, but TPO-RAs were more effective. Incidental COVID-19 infection was identified in a significant number of patients (9·5%), while 14 cases were thought to be secondary to COVID-19 vaccination.